Uzm. Dr. Safa Can Efil

Resection and pathological response after neoadjuvant nivolumab plus chemotherapy for lung cancer in a Turkish Oncology Group (TOG) real-world study

Research Square, 2026

DOI 10.21203/rs.3.rs-11204389/v1 Texte intégral en libre accèsSource : OpenAlex

Nutritional Indexes and Their Variations as Predictors of Atezolizumab Plus Chemotherapy Efficacy in Extensive-Stage Small Cell Lung Cancer: A Turkish Oncology Group Study

Journal of Immunotherapy, 2026

DOI 10.1097/cji.0000000000000610 PMID 42267536 Source : OpenAlex

Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study

Cancers, 2026

DOI 10.3390/cancers18132127 PMID 42449669 Texte intégral en libre accèsSource : OpenAlex

Prognostic impact of the Gustave Roussy Immune score in metastatic renal cell carcinoma treated with first-line immunotherapy-based combinations: results from the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

BMC Cancer, 2026

DOI 10.1186/s12885-026-16664-1 Texte intégral en libre accèsSource : OpenAlex

Comparison of 6 cycles with 4 cycles of chemotherapy and atezolizumab in the first-line treatment of ES-SCLC: a retrospective multicenter analysis

The oncologist, 2026

DOI 10.1093/oncolo/oyag092 PMID 41838398 Texte intégral en libre accèsSource : ORCID

Prognostic value of the glucose-to-lymphocyte ratio in surgically treated endometrial cancer: a retrospective cohort study

Future Oncology, 2026

DOI 10.1080/14796694.2026.2622299 PMID 41607196 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

Feasibility and Prognostic Value of an Ovarian NAR-like Score in Advanced Ovarian Cancer Treated with Neoadjuvant Chemotherapy and Interval Debulking Surgery

Journal of Clinical Medicine, 2026

DOI 10.3390/jcm15166266 PMID 42652669 Texte intégral en libre accèsSource : ORCID

Effects of Neoadjuvant Chemotherapy Treatment on Perioperative Outcomes Following Radical Cystectomy

The New Journal of Urology, 2026

DOI 10.33719/nju1831536 Texte intégral en libre accèsSource : ORCID

Association Between ABO Blood Group and Survival Outcomes in Advanced NSCLC Treated with Immune Checkpoint Inhibitors

2026

DOI 10.20944/preprints202606.1063.v1 Texte intégral en libre accèsSource : ORCID

Association Between ABO Blood Group and Survival Outcomes in Advanced NSCLC Treated with Immune Checkpoint Inhibitors

Current Oncology, 2026

DOI 10.3390/curroncol33100590 PMID 42930157 Texte intégral en libre accèsSource : OpenAlex

Real‐world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple‐negative breast cancer: A multicenter study by the Turkish Oncology Group

International Journal of Cancer, 2025

DOI 10.1002/ijc.70213 PMID 41147655 3 citations (Europe PMC) Source : OpenAlex

Comparative efficacy of adjuvant FOLFOX vs. FLOT following neoadjuvant FLOT in patients with locally advanced gastric cancer

Turkish journal of medical sciences, 2025

DOI 10.55730/1300-0144.6002 PMID 40686717 Texte intégral en libre accèsSource : Europe PMC

Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors—A Turkish Oncology Group Study

Cancers, 2025

DOI 10.3390/cancers18010101 PMID 41514612 1 citation (Europe PMC) Texte intégral en libre accèsSource : ORCID

FOLFIRINOX: The Best Adjuvant Treatment for Ampullary Adenocarcinoma? A Multicenter Study by the Turkish Oncology Group (TOG)

Cancers, 2025

DOI 10.3390/cancers17172730 PMID 40940827 Texte intégral en libre accèsSource : ORCID

FOLFIRINOX: The best adjuvant treatment for ampullary adenocarcinoma?

Journal of Clinical Oncology, 2025

DOI 10.1200/jco.2025.43.16_suppl.e16261 Source : ORCID

Prognostic impact of hand-foot skin reaction in regorafenib-treated adult-type diffuse gliomas: A multicenter Turkish Oncology Group study

Scientific Reports, 2025

DOI 10.1038/s41598-025-19899-3 PMID 41102268 Texte intégral en libre accèsSource : OpenAlex

Comparison of the Efficacy of First-Line Pemetrexed-Platinum and Gemcitabine-Platinum Regimens in Malignant Peritoneal Mesothelioma

Clinical Medicine Insights Oncology, 2025

DOI 10.1177/11795549251385075 PMID 41133016 Texte intégral en libre accèsSource : OpenAlex

Synergistic prognostic effect of the renin‐angiotensin‐aldosterone system and immune‐checkpoint inhibition in advanced lung cancer: The SPERICIL study

International Journal of Cancer, 2025

DOI 10.1002/ijc.70169 PMID 41045097 3 citations (OpenAlex) Source : OpenAlex

The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancer

Expert Review of Anticancer Therapy, 2025

DOI 10.1080/14737140.2025.2490289 PMID 40200428 3 citations (OpenAlex) Source : OpenAlex

Comparison of Frontline FOLFIRINOX with Fluorouracil-Based and Gemcitabine-Based Chemotherapies in Metastatic Ampullary Adenocarcinoma: A Multicenter Study by the Turkish Oncology Group (TOG)

Journal of Clinical Medicine, 2025

DOI 10.3390/jcm14165868 PMID 40869694 1 citation (Europe PMC) Texte intégral en libre accèsSource : ORCID

Comparison of frontline FOLFIRINOX with fluorouracil-based and gemcitabine-basedchemotherapies in metastatic ampullary adenocarcinoma: A multicenter cohort study.

Journal of Clinical Oncology, 2025

DOI 10.1200/jco.2025.43.16_suppl.e16264 Texte intégral en libre accèsSource : OpenAlex

Correlation of PD-L1 and HIF-1 Alpha Expression with KRAS Mutation and Clinicopathological Parameters in Non-Small Cell Lung Cancer

Current Issues in Molecular Biology, 2025

DOI 10.3390/cimb47020121 PMID 39996842 3 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Health-related quality of life and psychosocial outcomes in long-term survivors treated with immune checkpoint inhibitors: a nationwide multicenter study

Frontiers in Immunology, 2025

DOI 10.3389/fimmu.2025.1693295 PMID 41451229 3 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

Real-world evidence of ribociclib-induced hepatotoxicity in patients with breast cancer: a multi-center experience

BMC Cancer, 2025

DOI 10.1186/s12885-025-15181-x PMID 41316060 2 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

2079eP The NLA score as a prognostic biomarker in advanced driver-negative NSCLC treated with immunotherapy-based strategies

Annals of Oncology, 2025

DOI 10.1016/j.annonc.2025.08.2700 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

Comparative efficacy of adjuvant FOLFOX versus FLOT following neoadjuvant FLOT in locally advanced gastric cancer.

Journal of Clinical Oncology, 2025

DOI 10.1200/jco.2025.43.16_suppl.e16120 Texte intégral en libre accèsSource : OpenAlex

2822P Health-related quality of life and psychosocial outcomes in long-term survivors treated with ICIs: A nationwide multicenter study

Annals of Oncology, 2025

DOI 10.1016/j.annonc.2025.08.3434 Texte intégral en libre accèsSource : OpenAlex

Large Unstained Cells (LUC): A Novel Predictor of CDK4/6 Inhibitor Outcomes in HR+ HER2-Negative Metastatic Breast Cancer

Journal of Clinical Medicine, 2024

DOI 10.3390/jcm14010173 PMID 39797256 2 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Prognostic significance of pretreatment clinical and laboratory features in patients with ovarian cancer receiving neoadjuvant chemotherapy

Oncology in Clinical Practice, 2024

DOI 10.5603/ocp.100576 1 citation (OpenAlex) Texte intégral en libre accèsSource : ORCID

Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving Chemoimmunotherapy

Expert Opinion on Pharmacotherapy, 2024

DOI 10.1080/14656566.2024.2391007 PMID 39115275 4 citations (Europe PMC) Source : ORCID

A current comprehensive role of immune-checkpoint inhibitors in resectable non-small cell lung cancer: A narrative review

Journal of Oncology Pharmacy Practice, 2024

DOI 10.1177/10781552241260864 PMID 38860323 3 citations (Europe PMC) Source : ORCID

1875P Real-world evidence of ribociclib induced liver toxicity in patients with breast cancer: A multi-center experience

Annals of Oncology, 2024

DOI 10.1016/j.annonc.2024.08.1969 3 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

IMMUNOTHERAPY FOR CERVICAL CANCER

Turkiye Klinikleri eBooks, 2024

DOI 10.5336/978-625-395-244-0_p113 Source : OpenAlex

Prognostic and predictive value of tumor infiltrating lymphocytes in combination with systemic inflammatory markers in colon cancer

Clinics and Research in Hepatology and Gastroenterology, 2023

DOI 10.1016/j.clinre.2023.102171 PMID 37352926 19 citations (OpenAlex) Source : OpenAlex

Role of the prognostic nutritional index in the treatment prediction of stage II colon cancer

Research Square, 2023

DOI 10.21203/rs.3.rs-2786751/v1 Texte intégral en libre accèsSource : OpenAlex

456P Prognostic and predictive value of tumor-infiltrating lymphocytes in combination with systemic inflammatory markers in colon cancer

Annals of Oncology, 2021

DOI 10.1016/j.annonc.2021.08.977 2 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex